NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome (Q40098409)

17 September 2017

title

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome (English)

1 reference

17 September 2017

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Stephen Devereux

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Christopher P Fox

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Elizabeth Soilleux

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Toby A Eyre

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Ruth Clifford

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Adrian Bloor

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Lucy Boyle

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Corran Roberts

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Maite Cabes

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

George Follows

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

John Gribben

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Chris S Hatton

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Tim J Littlewood

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Helen McCarthy

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Jim Murray

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Andrew R Pettitt

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Basile Stamatopoulos

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sharon B Love

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Anna Schuh

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Peter Hillmen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Andrew Wotherspoon

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

5 July 2016

1 reference

British Journal of Haematology

17 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

175

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

43-54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma

10 June 2020

cites work

1 reference

Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature

21 January 2018

1 reference

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.

21 January 2018

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome

21 January 2018

1 reference

Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome

21 January 2018

1 reference

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia

21 January 2018

1 reference

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

21 January 2018

1 reference

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation

21 January 2018

1 reference

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

21 January 2018

1 reference

2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation.

21 January 2018

1 reference

Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients

21 January 2018

1 reference

Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome

21 January 2018

1 reference

The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation.

21 January 2018

1 reference

Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group

21 January 2018

1 reference

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

21 January 2018

1 reference

Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders

21 January 2018

1 reference

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

21 January 2018

1 reference

Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation

21 January 2018

1 reference

Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome

21 January 2018

1 reference

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.14177

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27378086%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference